The Judicial Panel for Multidistrict Litigation transferred all existing Invokana (canagliflozin) and Invokamet (canagliflozin/metformin) cases alleging ketoacidosis and kidney disease from federal courts across the country to the United States District Court for the District of New Jersey on December 7, 2016. A total of 55 cases alleging injuries from these diabetes drugs were transferred from Illinois, Kentucky, Minnesota, Missouri, Virginia and West Virginia to a consolidated docket before the Honorable Brian R. Martinotti.

Invokana and Invokamet are classified as sodium-glucose-cotransporter-2 drugs (a/k/a SGLT2 inhibitors). SGLT2s work by preventing the kidneys from reabsorbing blood sugar. This lets the sugar leave the body through the urine, and thereby lowers blood glucose levels. SGLT2s are prescribed for Type 2 diabetes.… Read More


The Food and Drug Administration recently issued a Drug Safety Communication warning doctors and patients that taking the new class of diabetes drugs known as SGLT2 inhibitors — including Invokana — may lead to high levels of blood acids called ketones, a serious medical condition called ketoacidosis. Diabetic ketoacidosis can cause a host of medical… Read More